Autolus Therapeutics plc 8-K

What Happened

• Autolus Therapeutics plc filed an 8-K reporting that its 2026 Annual General Meeting of Shareholders was held on June 29, 2026 and six resolutions were voted on and duly passed on a poll.
• Shareholders approved the 2025 Annual Report and Accounts; approved the Directors’ remuneration report (excluding the remuneration policy); appointed Ernst & Young LLP (US) as auditors for the year to the 2027 AGM; and re‑elected three directors: M. Bonney, Dr. E. Leiderman and R.W. Azelby.
• The vote counts (for/against/abstain) for each resolution were reported in the filing and are listed below.

Key Details

• Resolution 1 (adopt 2025 Annual Report and Accounts): For 165,846,326 / Against 2,895,344 / Abstain 75,901.
• Resolution 2 (approve Directors’ remuneration report): For 156,192,216 / Against 12,502,946 / Abstain 122,409.
• Resolution 3 (appoint Ernst & Young LLP (US) as auditors): For 165,871,368 / Against 2,872,225 / Abstain 73,978.
• Resolutions 4–6 (re‑elect directors):
  • M. Bonney: For 165,491,394 / Against 3,312,126 / Abstain 14,051.
  • Dr. E. Leiderman: For 165,741,204 / Against 3,063,838 / Abstain 12,529.
  • R.W. Azelby: For 162,133,091 / Against 6,671,776 / Abstain 12,704.

Why It Matters

• Governance continuity: Re‑election of board members and appointment of Ernst & Young LLP (US) as auditors maintain leadership and external oversight through the next AGM cycle, which is relevant for shareholders assessing corporate governance and audit continuity.
• Shareholder sentiment: All proposals passed with substantial support, though the Directors’ remuneration report drew a higher level of dissent (about 12.5 million votes against), a signal investors may watch for future pay and governance discussions.
• Filing context: The resolutions and vote results were disclosed in this 8‑K and follow details in the company’s definitive proxy statement filed June 5, 2026.